Curis, Inc.
CRIS Healthcare Biotechnology
Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024. In the quarter to June 2026, revenue fell 66.0%, EPS grew 70.4% and free cash flow fell 20.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CRIS
Curis, Inc. (CRIS) EV/Sales
As of 16 October 2026, Curis, Inc. (CRIS) trades at a EV/Sales of −0.4×. Over the past ten years it has ranged from −5.2× (May 2022) to 597× (February 2015); the current reading is higher than 12% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | 1,924.74% |
| FY2024 | 0.0× | (95.54%) |
| FY2023 | 1.1× | — |
| FY2022 | −2.6× | — |
| FY2021 | 30.2× | 41.41% |
| FY2020 | 21.3× | 116.86% |
| FY2019 | 9.8× | 201.04% |
| FY2018 | 3.3× | (64.75%) |
| FY2017 | 9.3× | (82.80%) |
| FY2016 | 53.9× | 41.02% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1.0× | (37.67%) |
| Sep 2025 | 1.6× | (12.60%) |
| Jun 2025 | 1.8× | — |
| Mar 2025 | −0.1× | — |
| 40 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LYRA Lyra Therapeutics, Inc. compare | −39.2× |
| MNTRQ 9 Meters Biopharma, Inc. compare | −0.5× |
| CRIS Curis, Inc. | −0.4× |
| BBLG Bone Biologics Corp. compare | n/m |
| PTIX Atrinsic Inc. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)